Table 1. Baseline demographics and characteristics (ITT populations).
| aboBoNT-A | Placebo | |
|---|---|---|
| n = 89 | n = 45 | |
| Female sex, n (%) | 59 (66.3) | 28 (62.2) |
| Age (years; mean ± SD) | 57.3 ± 11.11 | 56.5 ± 11.74 |
| Caucasian/white race, n (%) | 84 (94.4) | 42 (93.3) |
| Type of CD, n (%) | ||
| Torticollis | 75 (84.3) | 39 (86.7) |
| Laterocollis | 54 (60.7) | 30 (66.7) |
| Anterocollis | 17 (19.1) | 7 (15.6) |
| Retrocollis | 20 (22.5) | 8 (17.8) |
| Lateral shift | 22 (24.7) | 14 (31.1) |
| Sagittal shift | 9 (10.1) | 8 (17.8) |
| Previous exposure to botulinum neurotoxin, n (%) | ||
| Yes | 57 (64.0) | 29 (64.4) |
| No | 32 (36.0) | 16 (35.6) |
| Previous botulinum neurotoxin treatments for CD, n (%) | ||
| n* | 57/57 (100.00) | 29/29 (100.0) |
| onaBoNT-A | 56/57 (98.2) | 28/29 (96.6) |
| aboBoNT-A | 2/57 (3.5) | 1/29 (3.4) |
| incoBoNT-A | 6/57 (10.5) | 2/29 (6.9) |
| rimaBoNT-B | 5/57 (8.8) | 2/29 (6.9) |
| Most recent CD treatment with onaBoNT-A** | ||
| n | 55 | 25 |
| Mean dose*** (U; mean ± SD) | 177.0 ± 34.0 | 176.2 ± 42.2 |
| Mean time since last injection (months; mean ± SD) | 4.8 ± 19.1 | 3.6 ± 16.3 |
*Subjects may have been previously treated with ≥1 botulinum neurotoxin.
**In subjects who were non-naïve for onaBoNT-A treatment.
***Mean dose of onaBoNT-A exceeds 200 U eligibility requirement due to protocol deviations, patients were excluded from ITT.
aboBoNT-A = abobotulinumtoxinA; CD = cervical dystonia; incoBoNT-A = incobotulinumtoxinA; ITT = intent-to-treat; onaBoNT-A = onabotulinumtoxinA; rimaBoNt-B = rimabotulinumtoxinB; SD = standard deviation.